MétaCan
Menu
Back to cohort
Record W4404468660 · doi:10.1136/bmjment-2024-301165

Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose–response meta-analysis

2024· review· en· W4404468660 on OpenAlexaff
Yu‐Wei Lin, Yang‐Chieh Brian Chen, Kuo‐Chuan Hung, Chih‐Sung Liang, Ping‐Tao Tseng, André F. Carvalho, Eduard Vieta, Marco Solmi, Edward Chia‐Cheng Lai, Pao‐Yen Lin, Chih‐Wei Hsu, Yu‐Kang Tu

Bibliographic record

VenueBMJ Mental Health · 2024
Typereview
Languageen
FieldMedicine
TopicBipolar Disorder and Treatment
Canadian institutionsOttawa HospitalUniversity of Ottawa
FundersNational Science and Technology CouncilIdorsia PharmaceuticalsH. Lundbeck A/SCentro de Investigación Biomédica en Red de Salud MentalTeva Pharmaceutical IndustriesMinisterio de Ciencia e InnovaciónBiogenGedeon RichterPfizerDainippon Sumitomo PharmaSunovionSanofiAmgenNational Health Research InstitutesBristol-Myers Squibb
KeywordsLurasidoneMedicineMeta-analysisInternal medicineDepression (economics)Clinical Global ImpressionAnxietyBipolar disorderPlaceboGastroenterologyAntipsychoticPsychiatrySchizophrenia (object-oriented programming)Lithium (medication)

Abstract

fetched live from OpenAlex

QUESTION: The optimal dose of lurasidone for bipolar depression is unclear. This study examined its dose-response relationship for efficacy, acceptability, and metabolic/endocrine profiles. STUDY SELECTION AND ANALYSIS: Five databases and grey literature published until 1 August 2024, were systematically reviewed. The outcomes included efficacy (changes in depression, anxiety, clinical global impression, disability and quality of life), acceptability (dropout, manic switch, suicidality and side effects) and metabolic/endocrine profiles (changes in body weight, glucose, lipid and prolactin levels). Effect sizes were calculated using a one-step dose-response meta-analysis, expressed as standardised mean differences (SMDs), risk ratios (RRs) and mean differences (MDs) with 95% CIs. FINDINGS: Five randomised clinical trials (2032 patients, mean treatment duration 6 weeks) indicated that the optimal therapeutic dose of lurasidone (40-60 mg) improved depression (50 mg: SMD -0.60 (95% CI -0.30, -0.89)), anxiety (50 mg: -0.32 (95% CI -0.21, -0.42)), clinical global impression (50 mg: -0.67 (95% CI -0.30, -1.03)) and disability (50 mg: -0.38 (95% CI -0.08, -0.69)). Side effects increased with higher doses (50 mg: RR 1.15 (95% CI 1.05, 1.25); 100 mg: 1.18 (95% CI 1.02, 1.36)), but dropout, manic switch and suicidality did not show a dose-effect relationship. Weight increased at doses<60 mg (40 mg: MD 0.38 (95% CI 0.16, 0.60) kg), while blood glucose levels rose at doses>70 mg (100 mg: 3.16 (95% CI 0.76, 5.57) mg/dL). Prolactin levels increased in both males (50 mg: 3.21 (95% CI 1.59, 4.84) ng/mL; 100 mg: 5.61 (95% CI 2.42, 8.81)) and females (50 mg: 6.64 (95% CI 3.50, 9.78); 100 mg: 5.33 (95% CI 0.67, 10.00)). CONCLUSIONS: A daily dose of 40-60 mg of lurasidone is a reasonable choice for bipolar depression treatment. TRIAL REGISTRATION NUMBER: INPLASY202430069.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.026
metaresearch head score (Gemma)0.047
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.026
Threshold uncertainty score0.136

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0260.047
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0200.037
Bibliometrics0.0040.004
Science and technology studies0.0000.001
Scholarly communication0.0030.002
Open science0.0020.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.133
GPT teacher head0.482
Teacher spread0.349 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations13
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBMJ Mental HealthSame topicBipolar Disorder and TreatmentFrench-language works237,207